Canyon Labs, a leader in analytical & packaging lab testing and consulting for medical devices and pharmaceuticals, has agreed to acquire iuvo BioScience’s laboratory services and scientific consulting divisions, enabling both companies to accelerate their specialized growth trajectories.

The transaction positions Canyon Labs to deliver comprehensive end-to-end solutions in pharmaceutical and medical device development and strengthens iuvo BioScience’s focus on transformative ophthalmic clinical development contract research. The seamless transition includes the full integration of iuvo’s laboratory and consulting personnel into Canyon Labs’ operations, while iuvo BioScience retains its clinical research team and leadership structure.

“This acquisition marks a significant milestone in the growth of Canyon Labs’ capacity and capabilities,” said Sarah (Rosenblum) Ptach, President of Canyon Labs. “By strategically aligning our organizations, we are delivering immediate value to our global client base through faster lead times, expanded capacities, and unparalleled expertise at every step of the process. This integration strengthens our commitment to raising the standard of service in outsourced testing and consulting for the healthcare industry.”

“This transaction marks a defining moment for iuvo,” said Ben Burton, President and CEO of iuvo BioScience. “This strategic decision reinforces our fundamental mission of accelerating patient access to breakthrough vision care treatments. By sharpening our focus on our ophthalmic clinical contract research business, we’re strengthening our ability to provide the high touch, science-driven solutions our customers and partners have come to expect from iuvo.”

The announcement follows iuvo BioScience’s strategic acquisition of Promedica International, a specialized ophthalmology contract research organization, in early 2024.